Apoptotic Effects of Sanguinarine on the Organ of Corti 1 Cells: Comparison with Cisplatin

Abstract

OBJECTIVE:Sanguinarine is an alkaloid obtained from the root of Sanguinaria canadensis and other plants from the Papaveraceae family and is well known to possess a broad range of biological functions, such as antimicrobial, antifungal, anti-inflammatory, and antineoplastic activities. We aimed to specify the in vitro effect of sanguinarine on the House Ear Institute-Organ of Corti 1 (HEI-OC1) cells and to compare this effect with the ototoxic effect of cisplatin (CDDP). MATERIALS and METHODS:We performed cell proliferation assay for determining the in vitro effect of sanguinarine alone and compared it with the effect of cisplatin. Flow cytometry annexin-V apoptosis detection was performed. RESULTS:We found that sanguinarine and CDDP inhibited the cell growth in a dose-dependant manner in HEI-OC1 cells after 24 h of incubation. In sanguinarine-treated group, apoptosis was 6.6%, necrosis was 26.7%, and the cell viability was 66.7%. Further, in CDDP-treated group, apoptosis was 5.6%, necrosis was 45.4%, and the cell viability was 48.7%. According to the annexin-V apoptosis detection results, we found that sanguinarine caused 3.9% apoptosis and 1.3% necrosis, while CDDP caused 2.9% apoptosis and 20% necrosis on HEI-OC1 cells. CONCLUSION:Our findings suggested that lower doses of sanguinarine are promising antineoplastic agents, which did not indicate any toxic effect on HEI-OC1 cells. Application of these data to clinical practice requires further support by in vivo studies.

NLRX1 accelerates cisplatin-induced ototoxity in HEI-OC1 cells via promoting generation of ROS and activation of JNK signaling pathway

“…Meanwhile, the exposure of HEI-OC1 cells to cisplatin led to appear the typical characteristics of cells undergone apoptosis. These indicate that cisplatin is able to inhibit the growth of HEI-OC1 cells in vitro via triggering apoptotic pathway, which is consistent with previous studies in inner ear3334.…”

Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity

“…The cells were incubated at 33°C in a 10% CO 2 incubator [6] . KELLY (worse prognostic, MYC-N amplified) and SH-SY5Y (good prognostic, non-MYC-N amplified) neuroblastoma cells (DSMZ) were maintained in DMEM (Gibco™) and Rosewell Park Memorial Institute (RPMI)-1640 (Gibco™) containing 10% FBS, 1% penicillin/streptomycin, and 1% L-glutamine.…”

“…After incubation, 400 μL annexin-V binding buffer was added in each tube. Analyses were carried out using a flow cytometer (Accuri, BD) at 488 nm excitation and 530 nm emission wavelengths for annexin-V and 488 nm excitation and 647 nm emission wavelengths for 7-AAD, and evaluated using the BD Accuri C6 Software (BD Biosciences) [6] .…”

“…In neuroblastoma, the patient's age, tumor histology and stage, and cytogenetic and molecular genetic markers are the most important prognostic indicators [3] . Cisplatin (CDDP) is an anti-neoplastic agent that has been used in the treatment of both pediatric and adult cancers [3,6] . Although CDDP is used in cancer treatments, it has many side effects, such as ototoxicity, nephrotoxicity, and neurotoxicity [6,7] .…”

“…Cisplatin (CDDP) is an anti-neoplastic agent that has been used in the treatment of both pediatric and adult cancers [3,6] . Although CDDP is used in cancer treatments, it has many side effects, such as ototoxicity, nephrotoxicity, and neurotoxicity [6,7] . Although nephrotoxicity can be controlled and diminished after CDDP treatment, there is no prevention modality against CDDP ototoxicity in clinical practice [8,9] .…”